Share information
262.00 €
-2.31 %
06/02/2026 17:37
-2.31 %
Open
High
Low
Volume
263.80 €
266.00 €
258.30 €
177,200
Latest News
04-Feb-2026
UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements
30-Jan-2026
KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d)
13-Jan-2026
Innovation and Execution Power UCB’s Success
08-Dec-2025
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder